A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.

BMC Cancer · 2013 · PMC3827827 · PMID 24195809

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an encouraging trendno p-value reported

Discussion Molecular targeted therapies have created an encouraging trend in the management of cancer.

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.